论文部分内容阅读
目的观察POR*28基因多态性与阿托伐他汀调脂疗效的关系。方法采用聚合酶链反应-直接测序法对以阿托伐他汀治疗(20 mg,qn)30 d的185名高脂血症患者进行基因分型,比较治疗前后各基因型间血三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)及高密度脂蛋白胆固醇(HDL-C)水平的差别。结果 POR*28的基因变异率为41.6%,治疗前各基因型间TG、TC、LDL-C和HDL-C的浓度均无显著差异;治疗30 d后,纯合子等位基因TT型携带组LDL-C浓度显著低于CC型携带组[(2.46±0.37)mmol·L-1vs.(2.69±0.49)mmol·L-1,P=0.019],各基因组TG、TC浓度均无显著差异(P>0.05);TT型携带组HDL-C浓度有升高的趋势(P>0.05)。结论 POR*28基因多态性与阿托伐他汀降低LDL-C浓度有关。
Objective To observe the relationship between POR * 28 gene polymorphism and atorvastatin lipid regulation. Methods 185 cases of hyperlipidemia patients treated with atorvastatin (20 mg, qn) for 30 days were genotyped by polymerase chain reaction-direct sequencing. The levels of blood triglyceride TG, TC, LDL-C and HDL-C levels were measured. Results The gene mutation rate of POR * 28 was 41.6%. There was no significant difference in the concentrations of TG, TC, LDL-C and HDL-C among the genotypes before treatment. After 30 days of treatment, the homozygous TT allele carriers The concentration of LDL-C was significantly lower than that of CC group [(2.46 ± 0.37) mmol·L-1vs. (2.69 ± 0.49) mmol·L-1, P = 0.019] P> 0.05). The HDL-C concentration in TT-carrying group had an increasing trend (P> 0.05). Conclusion POR * 28 gene polymorphism and atorvastatin reduce LDL-C concentration.